Literature DB >> 24341887

Cancer immunotherapy using tumor cryoablation.

Abhinav Sidana1.   

Abstract

Cryoablation is increasingly being used as a primary treatment for localized cancers and as a salvage therapy for metastatic cancers. Anecdotal clinical reports and animal experiments have confirmed an induction of systemic antitumor immune response by tumor cryoablation. To capitalize on the stimulatory effects of cryoablation for cancer immunotherapy, this response must be intensified using other immunomodulatory agents. This article reviews the preclinical and clinical evidence and discusses the mechanism of the antitumor immune response generated by cryoablation. The rationale and evidence behind several immunotherapy approaches that can be combined with cryoablation to devise a cryoimmunotherapeutic strategy with a potential to impact the progression of metastatic disease are described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24341887     DOI: 10.2217/imt.13.151

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  11 in total

Review 1.  The Role of Ablation in Cancer Pain Relief.

Authors:  Dimitrios K Filippiadis; Steven Yevich; Frederic Deschamps; Jack W Jennings; Sean Tutton; Alexis Kelekis
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

2.  Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model.

Authors:  David J Tischfield; Alexey Gurevich; Omar Johnson; Isabela Gatmaytan; Gregory J Nadolski; Michael C Soulen; David E Kaplan; Emma Furth; Stephen J Hunt; Terence P F Gade
Journal:  Radiology       Date:  2022-01-11       Impact factor: 29.146

Review 3.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

4.  Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.

Authors:  Baorang Zhu; Ying Liu; Jing Li; Liyan Diao; Lin Shao; Han Han-Zhang; Lu Zhang; Qiaolin Kang; Wuwei Yang
Journal:  Oncologist       Date:  2019-12-17

5.  The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.

Authors:  Lei Chen; Yanqiao Ren; Tao Sun; Yanyan Cao; Liangliang Yan; Weihua Zhang; Tao Ouyang; Chuansheng Zheng
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

6.  Cryoablation In The Management Of Breast Cancer: Evidence To Date.

Authors:  Claudio Pusceddu; Panagiotis Paliogiannis; Giuseppe Nigri; Alessandro Fancellu
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-10-10

7.  Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.

Authors:  Xin Li; Jiahua Xu; Xiaoqiang Gu; Ling Chen; Qing Wu; Hongwei Li; Haoran Bai; Jinzu Yang; Jianxin Qian
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

Review 8.  Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.

Authors:  Kanishka Rangamuwa; Tracy Leong; Clare Weeden; Marie-Liesse Asselin-Labat; Steven Bozinovski; Michael Christie; Tom John; Phillip Antippa; Louis Irving; Daniel Steinfort
Journal:  Transl Lung Cancer Res       Date:  2021-06

9.  The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.

Authors:  Mi Zhang; Tianquan Yin; Yuan Lu; Huasong Feng
Journal:  Med Sci Monit       Date:  2016-04-19

10.  Establishment of a modified percutaneous CT-guided paraspinal intramuscular VX-2 squamous cell carcinoma dual tumor model in rabbits.

Authors:  Liangliang Meng; Husheng Shan; Xiaofeng He; Jiantao Zhou; Jingxiang Huang; Xin Zhang; Li Ma; Xiaodong Xue; Zhongliang Zhang; Yueyong Xiao
Journal:  PeerJ       Date:  2021-05-28       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.